Cerus Corporation (CERS)
Cerus Corporation Revenues: 8.782M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CERS Revenues Rankings
| Overall | 12th percentile | 3884 of 4425 |
| Sector | 30th percentile | 326 of 470 in Healthcare |
| Industry | 46th percentile | 71 of 132 in Biotechnology |
CERS Revenues Range, Past 5 Years
| Minimum | 2.395M | Dec 2007 |
| Maximum | 10.42M | Dec 2011 |
| Average | 5.411M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these CERS related companies
CERS News
Listen to $CERS Q1 2012 earnings call - live at 04:15 PM, ondemand after - http://stks.co/3bsn
about 27 days ago by earningscast
about 27 days ago by earningscast
$CERS http://stks.co/3Y76 Watching closely for a breakout. Attempted 1 and failed. Waiting for another.
about 31 days ago by jamiemc101
about 31 days ago by jamiemc101
$CERS filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3Wh8
about 32 days ago by MarketBrief
about 32 days ago by MarketBrief
Cantor Fitzgerald Starts Cerus (CERS) at Buy; Potential Game-Changer in Blood
Apr 16, 5:23PM Street Insider
Apr 16, 5:23PM Street Insider
Cerus Announces New Supply Agreement with Largest Blood Service in Saudi Arabia
Apr 03, 8:46AM Benzinga
Apr 03, 8:46AM Benzinga
Cerus Submits Investigational Device Exemption (IDE) Supplement to FDA for Phase III INTERCEPT Red Blood Cell Study
Mar 21, 8:30AM Business Wire
Mar 21, 8:30AM Business Wire
$CERS CEO: "2011 was our highest revenue year to date, driven by almost 40% growth in disposable kit demand yr over yr."
about 89 days ago by abubnic
about 89 days ago by abubnic
$CERS CEO: "We expect product revenue will continue to grow in 2012, with anticipated product revenue w/i range of $34-36M (11-18% growth)
about 89 days ago by abubnic
about 89 days ago by abubnic
Waiting for Bernanke. Stocks to Watch: $VVUS $SODA $CEDC $FSLR, $AAPL $CERS $LIZ http://stks.co/2btx
about 89 days ago by abubnic
about 89 days ago by abubnic
Cerus to Present at the Cowen and Company 32nd Annual Healthcare Conference on March 7, 2012
Feb 29, 8:30AM Business Wire
Feb 29, 8:30AM Business Wire
Listen to $CERS Q4 2011 earnings call - live at 04:15 PM, ondemand after - http://stks.co/2bHr
about 90 days ago by earningscast
about 90 days ago by earningscast
$CERS New 52 Week High - Crossed daily highs resistance. Next resistance 3.68 from 1/19/2011.
about 96 days ago by TradeIdeasQuant
about 96 days ago by TradeIdeasQuant
$CERS http://stks.co/2ULY bio name, LT chart looks really good - $CERS
about 97 days ago by LTbioinvestor
about 97 days ago by LTbioinvestor
Cerus to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
Feb 06, 8:30AM Business Wire
Feb 06, 8:30AM Business Wire
Cerus to Release Fourth Quarter and Year-End 2011 Results on February 28, 2012
Feb 02, 8:57AM Business Wire
Feb 02, 8:57AM Business Wire
Cerus and Ilex BioTech Report INTERCEPT Platelet and Plasma System Approvals in Israel
Feb 01, 8:30AM Business Wire
Feb 01, 8:30AM Business Wire
Cerus to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011
Dec 07, 8:30AM Business Wire
Dec 07, 8:30AM Business Wire
Cerus Announces Contracts for 19 New INTERCEPT Blood System Illuminators in Russia
Dec 06, 8:30AM Business Wire
Dec 06, 8:30AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CERS | 3.49 | -0.06 | -1.69% | 189.19M |
| CERN | 79.01 | -0.36 | -0.45% | 13.41B |
| CNGL | 0.3801 | +0.00 | +0.00% | 14.03M |
| CNET | 0.68 | -0.00 | -0.29% | 15.06M |
| CNC | 37.30 | +1.19 | +3.30% | 1.906B |
| CNBKA | 27.50 | +0.04 | +0.15% | 152.35M |
| CNBC | 10.11 | -0.05 | -0.49% | 165.10M |
| CNAM | 0.50 | -0.01 | -1.86% | 7.62M |
| CNAF | 25.25 | +0.25 | +1.00% | 72.22M |
| CNA | 28.56 | -0.15 | -0.52% | 7.693B |
